Women now have another drug option post-breast cancer surgery. The Food and Drug Administration approved a new use for FEMARA, a drug already used for treating advanced breast cancer. It can now be given to women past menopause who have early breast cancer.
Femera has been reported to be more effective at preventing recurrences than Tamoxifen.
Femara and Arimidex, a similar drug, are aromatase inhibitors, which block the production of estrogen, a hormone that fuels the growth of tumors that develop after menopause. Tomoxifen blunts the ability of estrogen to enter cells. Femara is made by Novartis.
Each year, approximately 800,000 women around the world are diagnosed with early breast cancer. Most of these women are of the type that would benefit from these drugs.